Ongoing and planned studies may support a tarcocimab BLA in 2026 and a potential KSI-501 BLA in 2027, while enabling complementary & potentially differentiated commercial profiles Indication Phase 3 Study Primary Endpoint 6-Month Durability Results / Progress Tarcocimab Retinal Vein Occlusion BEACON • Doubled treatment interval (Q8W) at PE (month 6) and ~50% of tarcocimab treated patients on 6-month dosing at Year 1 Diabetic Retinopathy GLOW1 • 100% of patients on 6-month dosing at Year 1 Wet AMD DAYLIGHT Not Applicable • Monthly study of tarcocimab demonstrated favorable safety and non-inferior efficacy at Year 1 Diabetic Retinopathy GLOW2 Superiority • Topline data on track for 1Q 2026 • Design mirrors successful GLOW1 study Wet AMD DAYBREAK Non- Inferiority • Enrollment complete • Topline data expected 3Q 2026 KSI-501 Wet AMD DAYBREAK Non- Inferiority Not Applicable • Enrollment complete • Topline data expected 3Q 2026 Not Specified 2nd Pivotal TBD TBD • In planning • Planned start in 2Q 2026 Completed Ongoing Planned 30 Ongoing